Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method

被引:50
作者
Jeong, YI [1 ]
Ohno, T
Hu, ZP
Yoshikawa, Y
Shibata, N
Nagata, S
Takada, K
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashima Ku, Kyoto 6078414, Japan
[2] Shionogi Qualicaps, Yamato Koriyama, Nara 6391032, Japan
关键词
colon delivery capsule; dipping method; intestinal luminal ethylcellulose; fluorescein; enteric polymer; first-appearance time in blood; beagle dogs;
D O I
10.1016/S0168-3659(01)00211-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A new method for preparation of large amounts of empty pressure-controlled colon delivery capsules (PCDCs) by a dipping method has been developed. Empty PCDCs are composed of two polymer membranes. The inner one was a water-insoluble polymer membrane, ethylcellulose (EC). The outer one was an enteric polymer membrane, hydroxypropylmethylcellulose phthalate (HPMCP) or hydroxypropylmethylcellulose acetate succinate (HPMCAS). By consequently dipping into an ethanolic EC solution and an alkalized enteric polymer solution, empty PCDCs were obtained after both the capsule body and cap were adjusted to the size of #2 capsules. With each enteric polymer, two types of empty PCDCs of different thickness were prepared. Fluorescein (FL) was formulated with suppository base, PEG1000, and used as a model drug. FL/PEG1000 suspension was introduced into empty PCDCs which were then sealed with enteric polymer solution. The PCDCs were evaluated by an in vivo experiment using beagle dogs, After oral administration of the rest PCDC preparations containing 30 mg of FL, blood samples were obtained from the jugular vein and serum FL levels were measured. The thickness of the EC membrane layer varied in both the capsule body and cap. HPMCAS PCDCs had 62.1 +/-5.0 (S.E.) mum (body) and 49.7 +/-3.3 mum (cap) with thicker ones and 55.7 +/-6.6 mum (body) and 46.8 +/-6.2 mum (cap) with thinner ones. HPMCP PCDCs had 28.1 +/-3.3 mum (body), 30.9 +/-1.0 mum (cap) with thinner ones and 43.1 +/-9.8 mum (body), 42.4 +/-8.2 mum (cap) with thicker ones, The mean T-i values, the first appearance time. of FL in the serum of HPMCAS PCDCs were 2.0 +/-0.7 h for thicker ones and 3.8 +/-0.5 h for thinner ones. while the mean T-i values of HPMCP PCDCs were 2.0 +/-0.0 h for thinner ones and 3.5 +/-0.7 h for thicker ones. Since the colon arrival time in beagle dogs was 3.5 +/-0.3 h as determined by a sulfasalazine test, thinner HPMCAS PCDCs and thicker HPMCP PCDCs were thought to deliver FL to the colon. (C) 2001 Elsevier Science B.V, All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 16 条
[1]  
DIGENIS GA, 1991, CRIT REV THER DRUG, V7, P309
[2]   Drug delivery to the colon [J].
Fish, NW ;
Bloor, JR .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (11) :1515-1521
[3]   Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects [J].
Hu, ZP ;
Mawatari, S ;
Shibata, N ;
Takada, K ;
Yoshikawa, H ;
Arakawa, A ;
Yosida, Y .
PHARMACEUTICAL RESEARCH, 2000, 17 (02) :160-167
[4]   New preparation method of intestinal pressure-controlled colon delivery capsules by coating machine and evaluation in beagle dogs [J].
Hu, ZP ;
Kimura, G ;
Mawatari, S ;
Shimokawa, T ;
Yoshikawa, Y ;
Takada, K .
JOURNAL OF CONTROLLED RELEASE, 1998, 56 (1-3) :293-302
[5]   Characterization of norfloxacine release from tablet coated with a new pH-sensitive polymer, P-4135F [J].
Hu, ZP ;
Shimokawa, T ;
Ohno, T ;
Kimura, G ;
Mawatari, SS ;
Kamitsuna, M ;
Yoshikawa, Y ;
Masuda, S ;
Takada, K .
JOURNAL OF DRUG TARGETING, 1999, 7 (03) :223-232
[6]  
KAMAGUCHI R, 1999, PHARM TECH JPN, V15, P1817
[7]   COMPARISON OF THE GASTROINTESTINAL ANATOMY, PHYSIOLOGY, AND BIOCHEMISTRY OF HUMANS AND COMMONLY USED LABORATORY-ANIMALS [J].
KARARLI, TT .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1995, 16 (05) :351-380
[8]   Review article - Colonic drug targeting [J].
Kinget, R ;
Kalala, W ;
Vervoort, L ;
van den Mooter, G .
JOURNAL OF DRUG TARGETING, 1998, 6 (02) :129-149
[9]   Peptide drug delivery: Colonic and rectal absorption [J].
Mackay, M ;
Phillips, J ;
Hastewell, J .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (02) :253-273
[10]  
MOES AJ, 1993, CRIT REV THER DRUG, V10, P143